National Costs for Cardiovascular-Related Hospitalizations and Inpatient Procedures in the United States, 2016 to 2021

被引:1
作者
Haidar, Amier [1 ]
Gajjar, Aryan [1 ]
V. Parikh, Rushi
Benharash, Peyman [3 ]
Fonarow, Gregg C. [2 ]
Watson, Karol [2 ]
Needleman, Jack [4 ]
Ziaeian, Boback [2 ,5 ]
机构
[1] UCLA, Dept Internal Med, David Geffen Sch Med, Los Angeles, CA USA
[2] UCLA, Div Cardiol, David Geffen Sch Med, Los Angeles, CA 90024 USA
[3] UCLA, Div Cardiac Surg, Cardiovasc Outcomes Res Labs CORELAB, David Geffen Sch Med, Los Angeles, CA USA
[4] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA
[5] VA Greater Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA 90024 USA
关键词
Cardiovascular hospitalizations; health care costs; National Inpatient Sample; ATRIAL-FIBRILLATION; TRENDS;
D O I
10.1016/j.amjcard.2024.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The current economic burden of cardiovascular (CV)-related hospitalizations grouped by diagnoses and procedures in the United States has not been well characterized. The objective was to identify current trends in CV-related hospitalizations, procedural utilization, and health care costs using the most recent 6 years of hospitalization data. A retrospective analysis of discharge data from the National Inpatient Sample database was conducted to determine trends in CV-related hospitalizations, costs, and procedures for each year from 2016 to the most recent available dataset, 2021. Total CV-related costs were adjusted to and reported in 2023 dollars. In 2021, there were 4,687,370 CV-related hospitalizations at a cost of $108 billion. Heart failure hospitalizations accounted for the highest costs at $18.5 billion, followed by non-ST-elevation myocardial infarction at $11.2 billion and stroke at $10.9 billion. Significant upward trends in costs from 2016 to 2021 were observed for heart failure, stroke, atrial fibrillation, ST-elevation myocardial infarction, chest pain, hypertensive emergency, ventricular tachycardia, aortic dissection, sudden cardiac death, pericarditis, supraventricular tachycardia, and pulmonary heart disease. Over the 6 observational years, total costs increased by over $10 billion, representing a 10% increase. However, the increases were not linear, as there was a significant increase of 6.5% from 2018 to 2019, then a decrease of over 7% from 2019 to 2020, followed by an increase of approximately 6% from 2020 to 2021. By 2030, total CV-related costs are projected to reach $131.3 billion. For all years, coronary procedures were the most performed, followed by extracorporeal membrane oxygenation, non-bypass peripheral vascular surgery, pacemaker placement, and coronary artery bypass graft surgery. Both transcatheter aortic valve replacement and MitraClip procedures demonstrated significant upward trends from 2016 to 2021. Overall, from the years 2016 to 2021, CV-related hospitalizations, costs, and procedures demonstrated upward trends. In conclusion, CV disease remains a high burden in the hospital setting with tremendous health care costs. (c) 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页码:63 / 70
页数:8
相关论文
共 32 条
  • [1] Agarwal M, 2021, CIRCULATION, V144
  • [2] National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017
    Agarwal, Manyoo A.
    Fonarow, Gregg C.
    Ziaeian, Boback
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 952 - 956
  • [3] Agency for Healthcare Research and Quality, Overview of the national (nationwide) inpatient sample (NIS)
  • [4] The Leading Causes of Death in the US for 2020
    Ahmad, Farida B.
    Anderson, Robert N.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (18): : 1829 - 1830
  • [5] Trends in Characteristics and Outcomes of Patients Undergoing Coronary Revascularization in the United States, 2003-2016
    Alkhouli, Mohamad
    Alqahtani, Fahad
    Kalra, Ankur
    Gafoor, Sameer
    Alhajji, Mohamed
    Alreshidan, Mohammed
    Holmes, David R.
    Lerman, Amir
    [J]. JAMA NETWORK OPEN, 2020, 3 (02)
  • [6] Arias E., 2022, Provisional life expectancy estimates for 2021
  • [7] Expenditure on Heart Failure in the United States
    Bhatnagar, Roshni
    Fonarow, Gregg C.
    Heidenreich, Paul A.
    Ziaeian, Boback
    [J]. JACC-HEART FAILURE, 2022, 10 (08) : 571 - 580
  • [8] Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic
    Bhatt, Ankeet S.
    Moscone, Alea
    McElrath, Erin E.
    Varshney, Anubodh S.
    Claggett, Brian L.
    Bhatt, Deepak L.
    Januzzi, James L.
    Butler, Javed
    Adler, Dale S.
    Solomon, Scott D.
    Vaduganathan, Muthiah
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (03) : 280 - 288
  • [9] Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016
    Birger, Maxwell
    Kaldjian, Alexander S.
    Roth, Gregory A.
    Moran, Andrew E.
    Dieleman, Joseph L.
    Bellows, Brandon K.
    [J]. CIRCULATION, 2021, 144 (04) : 271 - 282
  • [10] Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States
    Chew, Derek S.
    Sacks, Naomi C.
    Emden, Maia R.
    Preib, Madison T.
    Cyr, Philip L.
    Wood, David
    Pokorney, Sean D.
    [J]. AMERICAN HEART JOURNAL, 2021, 233 : 132 - 140